Evidence map›Paper›PMID 23717563›Full record

ArticlePloS one2013

Suppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell "dormancy".

Robert E Hurst, Paul J Hauser, Kimberly D Kyker, Jonathan E Heinlen, Jason P Hodde, Michael C Hiles, Stanley D Kosanke, Mikhail Dozmorov, Michael A Ihnat

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Autophagy and Cancer Dormancy.Frontiers in oncology · 2021
    Review
  4. Article
  5. Article
  6. Bioengineered models to study tumor dormancy.Journal of biological engineering · 2019
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Robert E HurstDepartment of Urology, College of Medicine, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States of America. Robert-hurst@ouhsc.edu
Paul J Hauser
Kimberly D Kyker
Jonathan E Heinlen
Jason P Hodde
Michael C Hiles
Stanley D Kosanke
Mikhail Dozmorov
Michael A Ihnat
OU HealthCook Biotech (United States) · USOklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · US

Funding

Drugs Targeting Dormant Tumors as Anti-Metastatic AgentsR44CA135867 · NCI · DORMATARG, INC. · PI IHNAT, MICHAEL A. · 2011 to 2012
$2.0M
Genes &Proteins of Urothelial-ECM InteractionR01DK069808 · NIDDK · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HURST, ROBERT EVAN · 2005 to 2009
$1.5M
BLADDER CANCER BIOMARKERS GUIDES TO SURGERY AND THERAPYR01CA075322 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HURST, ROBERT EVAN · 1999 to 2003
$1.4M
Single Agents with Designed Combination Chemotherapy PotentialR01CA136944 · NCI · DUQUESNE UNIVERSITY · PI GANGJEE, ALEEM · 2009 to 2010
$612k
Preventing bladder cancer recurrence and metastasisR43CA139804 · NCI · DORMATARG, INC. · PI HAUSER, PAUL · 2009 to 2009
$259k
Drugs Targeting Dormant Tumors as Anti-Metastatic AgentsR43CA135867 · NCI · DORMATARG, INC. · PI IHNAT, MICHAEL A. · 2008 to 2008
$122k
NCI NIH HHS R01 CA075322NCI NIH HHS R01 CA136944NCI NIH HHS R01 CA75322NCI NIH HHS R43 CA135867NCI NIH HHS R43 CA139804NCI NIH HHS R44 CA135867NIDDK NIH HHS R01 DK069808NIDDK NIH HHS R01 DK69808
6 · The paper itself

Abstract

A major problem in cancer research is the lack of a tractable model for delayed metastasis. Herein we show that cancer cells suppressed by SISgel, a gel-forming normal ECM material derived from Small Intestine Submucosa (SIS), in flank xenografts show properties of suppression and re-activation that are very similar to normal delayed metastasis and suggest these suppressed cells can serve as a novel model for developing therapeutics to target micrometastases or suppressed cancer cells. Co-injection with SISgel suppressed the malignant phenotype of highly invasive J82 bladder cancer cells and highly metastatic JB-V bladder cancer cells in nude mouse flank xenografts. Cells could remain viable up to 120 days without forming tumors and appeared much more highly differentiated and less atypical than tumors from cells co-injected with Matrigel. In 40% of SISgel xenografts, growth resumed in the malignant phenotype after a period of suppression or dormancy for at least 30 days and was more likely with implantation of 3 million or more cells. Ordinary Type I collagen did not suppress malignant growth, and tumors developed about as well with collagen as with Matrigel. A clear signal in gene expression over different cell lines was not seen by transcriptome microarray analysis, but in contrast, Reverse Phase Protein Analysis of 250 proteins across 4 cell lines identified Integrin Linked Kinase (ILK) signaling that was functionally confirmed by an ILK inhibitor. We suggest that cancer cells suppressed on SISgel could serve as a model for dormancy and re-awakening to allow for the identification of therapeutic targets for treating micrometastases.

Indexed as

PhenotypeAnimalsCell Culture TechniquesCell Line, TumorCluster AnalysisDisease Models, AnimalExtracellular MatrixGene ExpressionGenes, ReporterHeterograftsHumansKi-67 AntigenMiceProtein Array AnalysisProtein Serine-Threonine KinasesScaffold Protein ILKKi-67 AntigenProtein Serine-Threonine KinasesScaffold Protein ILKVimentin

Identifiers

PMID23717563
PMCPMC3663841
OpenAlexW1988556290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.